Peptone, a company involved in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), appointed key leaders to its executive management team and board of directors. Patrik Foerch has been appointed chief scientific officer; David Lowe, joins as senior vice president of protein therapeutics; and Benjamin Owens, previously chief strategy officer, has transitioned to the role of chief business officer and will join Peptone’s board of...